Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro [18F]-D-glucose

Cancer

Volumn 82, Issue 11, 1998, Pages 2227-2234

  Oshida, Masaki ^a   Uno, Kimiichi ^a   Suzuki, Masato ^a   Nagashima, Takeshi ^a   Hashimoto, Hideyuki ^a   Yagata, Hiroshi ^a   Shishikura, Tanetomo ^a   Imazeki, Keiko ^a   Nakajima, Nobuyuki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

2 Deoxy 2 fluoro 18F D glucose; Breast carcinoma; Positron emission tomography; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; FEMALE; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032103523     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980601)82:11<2227::AID-CNCR18>3.0.CO;2-W     Document Type: Article

References (28)

1. Warburg O. On the origin of cancer cells. Science 1956;123: 309-14.
2. Di Chiro G, De La Paz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-9.
3. Di Chiro G. Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1987;22:360-71.
4. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-9.
5. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-32.
6. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al. Evaluation of liver tumors using fluorine-18-fluoro-2-deoxy-D-glucose PET. J Nucl Med 1992;33: 339-44.
7. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991;32:1508-12.
8. 18F]fluorodeoxyglucose. Ann Surg Oncol 1997;4:57-63.
9. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-70.
10. Nieweg OE, Kim EE, Wong WH, Broussard WF. Singletary E, Hortobagyi GN, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920-5.
11. 18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995;21:280-3.
12. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
13. Mobbs BG, Johnson IE. Use of enzyme immunoassay (EIA) for quantitation of cytosolic and nuclear estrogen receptor, and correlation with progesterone receptor in human breast cancer. J Steroid Biochem 1987;28:653-62.
14. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
15. Knox WE, Jamdar SC, Davis PA. Hexokinase, differentiation and growth rate of transplanted rat tumors. Cancer Res 1970;30:2240-4.
16. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. Cancer 1993;72:2979-85.
17. Wahl RL, Helvie MA, Chang AE, Andersson I. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. J Nucl Med 1994; 35:872-5.
18. Adler LP, Crowe JP, Al-Kaishi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18]2-deoxy-2 fluoro-D-glucose PET. Radiology 1993;187:743-50.
19. Avril N, Dose J, Janicke F, Bense S, Ziegler S, Laubenbacher C, et al. Metabolie characterization of breast tumors with positron emission topography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-57.
20. Bassa P, Kim E, Inoue T, Wong FCL, Korkmaz M, Yang DJ, et al. Evaluaton of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-8.
21. Vitola JV, Delbeke D, Meranze SG, Mazer MJ, Pinson CW. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996;78:2216-22.
22. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62:816-22.
23. Barker FG II, Chang SM, Valk PE, Pounds TR, Prados MD. 18-fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115-26.
24. Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994;8:187-91.
25. Adler LP, Crowe JP, Al-Kaishi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18]2-deoxy-2 fluoro-D-glucose PET. Radiology 1993;187:743-50.
26. Bicknell R, Harris AL. Novel growth regulatory factors and tumor angiogenesis. Eur J Cancer 1991;27:781-5.
27. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML, et al. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-61.
28. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of longterm survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996;88:1764-9.